Every Form 4 that Revolution Medicines, Inc. (RVMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RVMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVMD filings page.
Horn Margaret A reported acquisition or exercise transactions in this Form 4 filing.
Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn reported equity awards consisting of a stock option for 47,600 shares and a grant of 21,100 shares of common stock. The option vests in equal monthly installments over four years starting March 1, 2026, contingent on her continued service.
Revolution Medicines, Inc. reported that General Counsel Jeff Cislini received equity awards. He was granted a stock option for 32,500 shares at an exercise price of $0.00 and an award of 14,500 shares of common stock. The option vests in equal monthly installments over four years starting on March 1, 2026, becoming fully vested on the fourth anniversary, subject to his continued service.
Revolution Medicines, Inc. reported that Chief Financial Officer Anders Jack acquired new equity awards. On March 1, 2026, he received a stock option covering 45,400 shares at an exercise price of $0.00 per share and a grant of 20,200 shares of common stock, both recorded as direct ownership.
The filing states that shares held include 62,538 restricted stock units. The option vests in equal monthly installments over 48 months starting March 1, 2026, so that all 45,400 option shares are fully vested and exercisable by the fourth anniversary, contingent on his continued service.
Revolution Medicines President and CEO Mark A. Goldsmith, who also serves as a director, reported an option exercise and updated share holdings. On February 6, 2026, a stock option for 24,010 shares with a $0.54 exercise price was converted into the same number of common shares.
Following the transaction, Goldsmith directly held 256,479 shares of common stock, which the filing notes includes 168,763 restricted stock units570,050 shares in the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust and 67,424 shares in each of two additional revocable trusts.
Revolution Medicines’ general counsel, Jeff Cislini, reported a small, pre-planned stock sale. On January 21, 2026, he sold 908 shares of Revolution Medicines common stock at $115.60 per share under a Rule 10b5-1 trading plan adopted on March 13, 2025. After this sale, he beneficially owned 46,976 shares, which include 38,769 restricted stock units that typically vest over time.
Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn reported a series of option exercises and share sales on January 7, 2026. She exercised stock options for 51,406 shares of common stock at $42.45 per share and 23,594 shares at $29.80 per share, then sold 53,096, 20,204 and 1,700 shares of common stock at weighted average prices of $100.0164, $101.7928 and $102.90, respectively. The transactions were made under a Rule 10b5-1 trading plan adopted on March 7, 2025. After these trades, she directly beneficially owned 141,053 shares of common stock, which include 61,226 restricted stock units, and held remaining stock options covering 1,094 and 119,906 shares with vesting described in the filing.
Revolution Medicines Chief Financial Officer Jack Anders reported an exercise and sale of company stock. On January 7, 2026, he exercised a stock option for 10,000 shares of common stock at an exercise price of $42.45 per share, then sold 10,000 shares of common stock at a price of $98 per share. The filing states this activity was carried out under a Rule 10b5-1 trading plan adopted on December 16, 2024, indicating it was pre‑scheduled. Following these transactions, Anders beneficially owned 108,065 shares of common stock, which includes 42,338 restricted stock units, and held 15,900 stock options directly.
Revolution Medicines, Inc. reported an insider transaction by its General Counsel, who filed a Form 4 as a single reporting person. On 12/16/2025, the officer sold 2,688 shares of common stock at a price of $76.8169 per share. After this sale, the reporting person beneficially owned 47,884 shares.
The transaction was made pursuant to a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023, to satisfy tax withholding obligations upon vesting of restricted stock units (RSUs) after July 15, 2023. The reported holdings include 147 shares acquired under the company’s Employee Stock Purchase Plan on November 30, 2025, and 38,769 RSUs, which represent additional equity that may be delivered over time as they vest.
Revolution Medicines, Inc. insider transaction: President and Chief Executive Officer Mark A. Goldsmith, who is also a director, reported selling 15,394 shares of Revolution Medicines common stock on 12/16/2025 at a price of $76.8173 per share. The sale was made under a Rule 10b5-1 instruction letter adopted on May 31, 2023 to cover tax withholding obligations arising from the vesting of restricted stock units.
After this transaction, Goldsmith beneficially owns 232,469 shares directly, which includes 168,763 restricted stock units. He also holds additional indirect interests through trusts, including 67,424 shares held by the Jonathan Goldsmith Revocable Trust, 67,424 shares held by the Rebecca Goldsmith Revocable Trust, and 570,050 shares held by the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
Revolution Medicines, Inc. reported that officer Stephen Michael Kelsey, President of Research and Development, disposed of 5,447 shares of common stock on 12/16/2025 at a price of $76.8172 per share. This sale was coded as an "S" transaction and was made under a Rule 10b5-1 instruction letter adopted on May 31, 2023 to cover tax withholding obligations related to restricted stock unit (RSU) vesting after July 15, 2023. Following this transaction, Kelsey beneficially owned 278,600 shares of common stock, including 73,576 RSUs.
Revolution Medicines, Inc. Chief Operating Officer Margaret Horn reported a sale of company stock in an insider filing. On 12/16/2025, she disposed of 4,847 shares of common stock at a price of $76.8173 per share. The filing states this transaction was executed under a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023, to cover tax withholding obligations triggered by the vesting of restricted stock units.
After this transaction, Horn beneficially owned 141,053 shares of Revolution Medicines common stock, which includes 61,226 restricted stock units. The form indicates the holdings are directly owned.
Revolution Medicines, Inc. Chief Financial Officer reports a planned share sale. CFO Jack Anders disclosed the sale of 3,104 shares of common stock on 12/16/2025 at a price of $77.0904 per share. The transaction was made under a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy his tax withholding obligations upon the vesting of restricted stock units after July 15, 2023.
Following this transaction, Anders beneficially owns 108,065 shares of Revolution Medicines common stock. This figure includes 175 shares acquired under the company’s Employee Stock Purchase Plan on November 30, 2025 and 42,338 restricted stock units, which represent a right to receive shares in the future subject to vesting conditions.
Revolution Medicines, Inc. (RVMD) reported an insider stock transaction by its Chief Financial Officer, Jack Anders. On 11/25/2025, Anders exercised a stock option for 5,418 shares of common stock at an exercise price of $17 per share, then sold 5,418 shares of common stock at a price of $74 per share. The filing notes that the transaction was made under a Rule 10b5-1 trading plan adopted on December 16, 2024, which is designed to pre-arrange trades. After these transactions, Anders directly holds 110,994 shares of common stock, which includes 48,275 restricted stock units.
Revolution Medicines, Inc. (RVMD) reported insider activity by President, Chief Executive Officer and Director Mark A. Goldsmith. On 11/25/2025, he exercised a stock option to buy 60,000 shares of common stock at an exercise price of $4.09 per share, then sold 60,000 shares of common stock in a transaction under code M/S.
He also reported open market sales of 3,000 shares of common stock at $75 per share from each of two trusts. A weighted average sale price of $75.0827 was reported for one of the sales executed in multiple trades. After these transactions, he directly beneficially owned 247,863 shares of common stock (including 193,475 restricted stock units), and held additional indirect positions of 67,424 shares in each of two revocable trusts and 570,050 shares in a separate revocable living trust. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2024.
Revolution Medicines (RVMD) President and CEO Mark A. Goldsmith reported an option exercise and stock sale. On 11/18/2025, he exercised a stock option for 20,000 shares of common stock at an exercise price of $4.09 per share, then sold 20,000 shares of common stock in open market transactions at a weighted average price of $70.3793 per share.
After these transactions, he directly beneficially owned 247,863 shares of common stock, which includes 193,475 restricted stock unitsRule 10b5-1 trading plan adopted on December 19, 2024, indicating the trades were pre-arranged under that plan.
Revolution Medicines, Inc. (RVMD) reported an insider equity transaction by its General Counsel, who is an officer of the company. On 11/18/2025, the officer exercised a stock option for 13,388 shares of common stock at an exercise price of $42.45 per share, then sold 13,388 shares of common stock on the same date at a weighted average price of $70.138 per share. After these transactions, the officer beneficially owned 50,425 shares of common stock, which includes 43,910 restricted stock units. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025.
Revolution Medicines (RVMD) reported an insider transaction on a Form 4. CFO Jack Anders exercised 10,000 stock options at $17 and sold 10,000 common shares at $64 on November 11, 2025 pursuant to a Rule 10b5-1 plan adopted on December 16, 2024.
After these transactions, Anders beneficially owned 110,994 shares, which include 48,275 restricted stock units. The option exercised related to an award with a $17 exercise price (exercisable from 02/12/2024 to 02/11/2030), with 5,418 derivative securities remaining beneficially owned.
Revolution Medicines (RVMD) — Form 4 insider activity: President and CEO Mark A. Goldsmith reported option exercises and share sales on 11/07/2025 pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2024. He exercised options for 26,479 shares at $1.12 and 3,521 shares at $4.09, then sold 30,000 shares at a weighted average price of $60.3102 (trades ranged from $60.00 to $60.88).
On 11/12/2025, he recorded transfers of 50,000 shares to the Jonathan Goldsmith Revocable Trust and 50,000 shares to the Rebecca Goldsmith Revocable Trust, and reported indirect holdings in multiple family trusts. Following the transactions, direct beneficial ownership amounts were updated across entries, and his beneficial holdings include 193,475 restricted stock units.